Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

Phase 2 Completed 22 enrolled University of Wisconsin, Madison

NaSingle-groupOpen-labelTreatment

Summary

rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

Timeline

Start: 2000-06
Primary completion: 2006-06
Completion: 2010-03

Publications

Results Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, Rezazedeh H, Werndli J, Bailey HH; Wisconsin Oncology Network. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol. 2006 Sep;17(9):1418-23. doi: 10.1093/annonc/mdl127. Epub 2006 Jun 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	—	—
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Dexamethasone	Small molecule	—	—
Background	Doxorubicin	Other / unclassified	—	—
Background	Vincristine	Small molecule	—	—

Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

Summary

Timeline

Publications

Drugs

Indications